Pathstone Family Office, LLC X4 Pharmaceuticals, Inc Transaction History
Pathstone Family Office, LLC
- $15.6 Billion
- Q3 2023
A detailed history of Pathstone Family Office, LLC transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Pathstone Family Office, LLC holds 12,637 shares of XFOR stock, worth $6,950. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,637Holding current value
$6,950% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding XFOR
# of Institutions
106Shares Held
103MCall Options Held
206KPut Options Held
291K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$9.3 Million3.55% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$8.24 Million1.46% of portfolio
-
Black Rock Inc. New York, NY8.74MShares$4.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.83MShares$4.31 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$3.92 Million0.22% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $37.8M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...